Twist Bioscience

• 8-K

  Filed Aug 19

  Shares issuable to Invenra under the February stock purchase agreement are being registered for resale pursuant to registration rights.

• 8-KContract / partnership

  Filed Aug 18

  Anthropic selected Twist to independently evaluate AI-designed proteins through scaled production and binding tests.

• 8-KEquity raise

  Filed Aug 5

  Upsized stock offering to fund R&D, manufacturing capacity and product offerings; underwriters exercised their option in full.

• 10-QQ3 FY2026Legal / investigation

  Filed Aug 3

  Therapeutics and DNA synthesis drove growth beyond NGS, but SG&A expansion outpaced revenue and widened the operating loss.

  • Revenue$118.4MYoY +23.2%
  • Net income−$35.1Mvs $20.4M year ago

• 8-KPositiveEarningsGuidance raised

  Filed Aug 3

  DNA Synthesis and Protein Solutions led growth as FY2026 revenue guidance rose; Q4 adjusted EBITDA breakeven target reaffirmed.

• 10-QQ2 FY2026Impairment / chargeLegal / investigation

  Filed May 4

  Therapeutics demand and higher gene shipments lifted DNA and protein sales, but litigation and commercial spending widened losses.

  • Revenue$110.7MYoY +19.3%
  • Net income−$44.0MYoY −11.9%

• 8-KPositiveEarningsGuidance raisedImpairment / chargeLegal / investigation

  Filed May 4

  DNA Synthesis and Protein Solutions leads growth; FY2026 revenue outlook raised and Q4 adjusted EBITDA breakeven reaffirmed.

• 8-KDeal pendingContract / partnershipEquity raise

  Filed Feb 17

  Invenra license and technology transfer deal pairs cash and stock payments with an equity stake and the right to designate a director.

• 8-KShareholder vote

  Filed Feb 6

  Shareholders approved executive pay, elected three directors and ratified Ernst & Young as FY2026 auditor.

• 10-QQ1 FY2026Positive

  Filed Feb 2

  Therapeutics demand and global supply partners lifted DNA synthesis sales; process savings widened margins, but higher commercial costs limited loss improvement.

  • Revenue$103.7MYoY +16.9%
  • Net income−$30.5MYoY +3.4%

• 8-KPositiveEarningsGuidance raised

  Filed Feb 2

  DNA Synthesis and NGS growth support raised FY2026 revenue guidance; Q4 adjusted EBITDA breakeven target reaffirmed.

• 8-KPositiveEarnings

  Filed Jan 12

  NGS Applications outpaced guidance as preliminary revenue topped outlook; momentum is expected to continue into Q2.

• 10-QQ3 FY2025Positive

  Filed Aug 4, 2025

  Atlas divestiture refocused resources on synthetic DNA/RNA and NGS; higher volumes and manufacturing efficiencies expanded gross margin.

  • Revenue$96.1MYoY +17.9%
  • Net income$20.4Mvs −$85.6M year ago

Coverage: 10-Q filings filed since Aug 4, 2025; 8-K since Jan 12, 2026.

Request longer coverage

Company data: Wikidata Q43303430